Developing an Asymptomatic Mucosal Herpes Vaccine: the Present and the Future

Overview

Journal Future Microbiol

Specialties Infectious Diseases
Microbiology

Date 2009 Dec 22

PMID 20020824

Citations 28

Authors

Gargi Dasgupta

Anthony B Nesburn

Steven L Wechsler

Lbachir BenMohamed

Affiliations

Soon will be listed here.

Citing Articles

Solidified reverse micellar solution-based chitosan-coated solid lipid nanoparticles as a new approach to enhance oral delivery of artemether in malaria treatment.

Kenechukwu F, Ugwu K, Offorbuike C, Ojukwu E, Gugu T, Eze R BMC Chem. 2025; 19(1):64.

PMID: 40057800 PMC: 11890727. DOI: 10.1186/s13065-025-01422-4.

Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4 and CD8 T cells and protects against recurrent....

Quadiri A, Prakash S, Dhanushkodi N, Singer M, Zayou L, Shaik A J Virol. 2024; 98(5):e0159623.

PMID: 38587378 PMC: 11092353. DOI: 10.1128/jvi.01596-23.

Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+CD44+ CD62L-CD8+ T Cells and Memory CCR10+B220+CD27+ B Cells into the Infected Vaginal Mucosa.

Dhanushkodi N, Prakash S, Quadiri A, Zayou L, Srivastava R, Tran J J Immunol. 2023; 211(1):118-129.

PMID: 37222480 PMC: 10330291. DOI: 10.4049/jimmunol.2300093.

Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back.

Chentoufi A, Dhanushkodi N, Srivastava R, Prakash S, Coulon P, Zayou L Front Immunol. 2022; 13:849515.

PMID: 35547736 PMC: 9082490. DOI: 10.3389/fimmu.2022.849515.

Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4 and CD8 T Cells Associated with Protection against....

Srivastava R, Roy S, Coulon P, Vahed H, Prakash S, Dhanushkodi N J Virol. 2019; 93(9).

PMID: 30787156 PMC: 6475797. DOI: 10.1128/JVI.02309-18.

References

Koelle D, Corey L . Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev. 2003; 16(1):96-113. PMC: 145296. DOI: 10.1128/CMR.16.1.96-113.2003. View

Koelle D, Liu Z, McClurkan C, Cevallos R, Vieira J, Hosken N . Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A. 2003; 100(22):12899-904. PMC: 240716. DOI: 10.1073/pnas.2131705100. View

Chentoufi A, Binder N, Berka N, Durand G, Nguyen A, Bettahi I . Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J Virol. 2008; 82(23):11792-802. PMC: 2583686. DOI: 10.1128/JVI.00692-08. View

Oram R, Marcellino D, Strauss D, Gustafson E, Talarico C, Root A . Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate. J Infect Dis. 2000; 181(4):1458-61. DOI: 10.1086/315387. View

BenMohamed L, Wechsler S, Nesburn A . Lipopeptide vaccines--yesterday, today, and tomorrow. Lancet Infect Dis. 2002; 2(7):425-31. DOI: 10.1016/s1473-3099(02)00318-3. View

Czartoski T, Liu C, Koelle D, Schmechel S, Kalus A, Wald A . Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman. J Clin Microbiol. 2006; 44(4):1584-6. PMC: 1448683. DOI: 10.1128/JCM.44.4.1584-1586.2006. View

Divito S, Cherpes T, Hendricks R . A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency. Immunol Res. 2007; 36(1-3):119-26. DOI: 10.1385/IR:36:1:119. View

Zhang X, Issagholian A, Berg E, Fishman J, Nesburn A, BenMohamed L . Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J Virol. 2005; 79(24):15289-301. PMC: 1316035. DOI: 10.1128/JVI.79.24.15289-15301.2005. View

Schinazi R, Del Bene V, Scott R . Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency. J Antimicrob Chemother. 1986; 18 Suppl B:127-34. DOI: 10.1093/jac/18.supplement_b.127. View

10.

Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss H, Vergne L . Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007; 356(8):790-9. DOI: 10.1056/NEJMoa062607. View

11.

Zhang X, Chentoufi A, Dasgupta G, Nesburn A, Wu M, Zhu X . A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2009; 2(2):129-143. PMC: 4509510. DOI: 10.1038/mi.2008.81. View

12.

BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P . Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol. 2002; 32(8):2274-81. DOI: 10.1002/1521-4141(200208)32:8<2274::AID-IMMU2274>3.0.CO;2-C. View

13.

Perng G, Maguen B, Jin L, Mott K, Kurylo J, BenMohamed L . A novel herpes simplex virus type 1 transcript (AL-RNA) antisense to the 5' end of the latency-associated transcript produces a protein in infected rabbits. J Virol. 2002; 76(16):8003-10. PMC: 155148. DOI: 10.1128/jvi.76.16.8003-8010.2002. View

14.

Dasgupta G, Chentoufi A, Nesburn A, Wechsler S, BenMohamed L . New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines. 2009; 8(8):1023-35. PMC: 2760836. DOI: 10.1586/erv.09.60. View

15.

Zhu X, Ramos T, Gras-Masse H, Kaplan B, BenMohamed L . Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol. 2004; 34(11):3102-14. DOI: 10.1002/eji.200425166. View

16.

Mancini-Bourgine M, Bayard F, Soussan P, Deng Q, Lone Y, Kremsdorf D . Hepatitis B virus splice-generated protein induces T-cell responses in HLA-transgenic mice and hepatitis B virus-infected patients. J Virol. 2007; 81(10):4963-72. PMC: 1900232. DOI: 10.1128/JVI.02619-06. View

17.

Nesburn A, Bettahi I, Zhang X, Zhu X, Chamberlain W, Afifi R . Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul Surf. 2006; 4(4):178-87. DOI: 10.1016/s1542-0124(12)70164-7. View

18.

Weiss H . Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes. 2004; 11 Suppl 1:24A-35A. View

19.

Langenberg A, Corey L, Ashley R, Leong W, Straus S . A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med. 1999; 341(19):1432-8. DOI: 10.1056/NEJM199911043411904. View

20.

Mott K, Chentoufi A, Carpenter D, BenMohamed L, Wechsler S, Ghiasi H . The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on virus replication and pathogenicity. Invest Ophthalmol Vis Sci. 2009; 50(6):2903-12. DOI: 10.1167/iovs.08-2957. View